Back to search

Article

Comparison of Moderna Versus Pfizer-Biontech COVID-19 Vaccine Outcomes: A Target Trial Emulation Study In the U.S. Veterans Affairs Healthcare System

2022-01-07

Abstract excerpt

Background: mRNA COVID-19 vaccines manufactured by Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) have been shown to be efficacious but have not been compared in head-to-head clinical trials.<br><br>Methods: We designed this observational study to emulate a target trial of COVID-19 vaccination by BNT162b2 versus mRNA-1273 among persons who underwent vaccination in the national U.S. Veterans Affairs (VA) health...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
457ecfa3-5f71-5ce0-a83e-87aaa7c96b84
DOI
10.2139/ssrn.4003207
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Comparison of Moderna Versus Pfizer-Biontech COVID-19 Vaccine Outcomes: A Target Trial Emulation Study In the U.S. Veterans Affairs Healthcare SystemDOI 10.2139/ssrn.4003207
Comparative effectiveness of mRNA-1273 versus protein-based NVX-CoV2705 vaccination on COVID-19-related outcomes among US insured adults during 2024–2025: a retrospective matched cohort studySemantic proximity
Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine (mRNA-1273.815) in preventing COVID-19-related hospitalizations and medical encounters among adults in the United States: An interim analysisSemantic proximity
Modeling the Anticipated Public Health Benefits of the Next-Generation COVID-19 mRNA-1283 vaccine: An Interim U.S. Population-Level Impact AssessmentSemantic proximity
Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United StatesSemantic proximity
Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE FrameworkSemantic proximity
Effectiveness of the 2023–2024 Omicron XBB.1.5-containing mRNA COVID-19 Vaccine (mRNA-1273.815) in Preventing COVID-19–related Hospitalizations and Medical Encounters Among Adults in the United StatesSemantic proximity
Comparative Effectiveness of the mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults With Underlying Medical Conditions: A Systematic Literature Review and Pairwise Meta-Analysis Using GRADESemantic proximity
Real-World Effectiveness of the mRNA-1273 Vaccine Against COVID-19: Interim Results from a Prospective Observational Cohort StudySemantic proximity
Real-world effectiveness and non-inferiority evaluation and comparison of mRNA- and protein-based COVID-19 vaccines: a randomized study protocol (BEEHIVE)Semantic proximity
Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada: a test-negative design studySemantic proximity
Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in FranceSemantic proximity
Clinical and Economic Impact of Differential COVID-19 Vaccine Effectiveness in the United StatesSemantic proximity
Select a neighboring publication to make it the new centre.